These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 31400410

  • 1. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y, Luong M, Guadiz C, Zhang M, Gorovits B.
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [Abstract] [Full Text] [Related]

  • 2. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
    Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M.
    Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
    Nair-Gupta P, Rudnick SI, Luistro L, Smith M, McDaid R, Li Y, Pillarisetti K, Joseph J, Heidrich B, Packman K, Attar R, Gaudet F.
    Blood Cancer J; 2020 Jun 01; 10(6):65. PubMed ID: 32483120
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A.
    Lancet; 2021 Aug 21; 398(10301):665-674. PubMed ID: 34388396
    [Abstract] [Full Text] [Related]

  • 9. Addressing Domain Specificity in the Development of a Cell-Based Binding Assay for the Detection of Neutralizing Antibodies Against a CD47xPD-L1 Bispecific Antibody.
    Luong M, Wang Y, Donnelly BB, Lepsy C.
    AAPS J; 2023 Sep 22; 25(6):91. PubMed ID: 37740131
    [Abstract] [Full Text] [Related]

  • 10. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF, Anderson KC, Tai YT.
    Front Immunol; 2018 Sep 22; 9():1821. PubMed ID: 30147690
    [Abstract] [Full Text] [Related]

  • 11. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
    Fei K, Ni H, Zhu M, Kuang Z, Wu M, Wu Z, Wang F, Zhou S, Jing H, Wu W, Wu D, Bai D, Chen B.
    Cancer Lett; 2022 Jun 28; 536():215663. PubMed ID: 35381307
    [Abstract] [Full Text] [Related]

  • 12. Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy.
    Irvin SC, D'Orvilliers A, Bloch N, Boccio K, Pennucci J, Brouwer-Visser J, Ullman E, Rajadhyaksha M, Hassanein M, Potocky T, Torri A, Hermann A, Partridge MA.
    AAPS J; 2022 Jun 21; 24(4):76. PubMed ID: 35725847
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N, Chari A, Scott E, Mezzi K, Usmani SZ.
    Leukemia; 2020 Apr 21; 34(4):985-1005. PubMed ID: 32055000
    [Abstract] [Full Text] [Related]

  • 16. Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab.
    Frerichs KA, Broekmans MEC, Marin Soto JA, van Kessel B, Heymans MW, Holthof LC, Verkleij CPM, Boominathan R, Vaidya B, Sendecki J, Axel A, Gaudet F, Pillarisetti K, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ.
    Clin Cancer Res; 2020 May 01; 26(9):2203-2215. PubMed ID: 31969333
    [Abstract] [Full Text] [Related]

  • 17. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I, Bago JR, Hajek R, Jelinek T.
    Br J Haematol; 2021 May 01; 193(4):705-722. PubMed ID: 33216972
    [Abstract] [Full Text] [Related]

  • 18. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E, Krumbholz M.
    Curr Opin Immunol; 2021 Aug 01; 71():117-123. PubMed ID: 34330018
    [Abstract] [Full Text] [Related]

  • 19. A Flexible Multiplatform Bioanalytical Strategy for Measurement of Total Circulating Shed Target Receptors: Application to Soluble B Cell Maturation Antigen Levels in the Presence of a Bispecific Antibody Drug.
    Stauffer A, Ray C, Hall M.
    Assay Drug Dev Technol; 2021 Jan 01; 19(1):17-26. PubMed ID: 33232610
    [Abstract] [Full Text] [Related]

  • 20. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
    Chen H, Yu T, Lin L, Xing L, Cho SF, Wen K, Aardalen K, Oka A, Lam J, Daley M, Lu H, Munshi N, Anderson KC, Tai YT.
    Blood Cancer J; 2022 Aug 16; 12(8):118. PubMed ID: 35973981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.